Article
Medicine, Research & Experimental
Fuyuki F. Inagaki, Hiroaki Wakiyama, Aki Furusawa, Ryuhei Okada, Takuya Kato, Daiki Fujimura, Shuhei Okuyama, Hiroshi Fukushima, Seiichiro Takao, Peter L. Choyke, Hisataka Kobayashi
Summary: Bones are a common site for metastasis from solid tumors, and current treatments are not curative. Near-infrared photoimmunotherapy (NIR-PIT), which uses antibodies labeled with IRDye700DX (IR700) activated by NIR light, has shown success in treating head and neck cancer but has not been tested on bone metastases. This study investigated the efficacy of EGFR-targeted NIR-PIT on bone metastatic lesions using a mouse model and found that it had a therapeutic effect and could repair metastasis-induced bone destruction.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Review
Oncology
Hiroshi Fukushima, Baris Turkbey, Peter A. Pinto, Aki Furusawa, Peter L. Choyke, Hisataka Kobayashi
Summary: Near-infrared photoimmunotherapy (NIR-PIT) is a novel molecularly-targeted therapy that selectively kills cancer cells by injecting an antibody-photoabsorber conjugate (APC) that binds to cancer cells, followed by the application of NIR light. NIR-PIT can selectively kill cancer cells without harming normal tissues and activates anti-cancer immunity.
Review
Medicine, General & Internal
Yasuhiro Maruoka, Hiroaki Wakiyama, Peter L. Choyke, Hisataka Kobayashi
Summary: Near-infrared photoimmunotherapy (NIR-PIT) is a highly-selective cancer treatment using a photoabsorbing dye, currently undergoing global phase III clinical trials and conditionally approved in Japan. In addition to rapid, selective cancer cell death, it also stimulates anti-tumour immunity and may have improved results in combination with immune-checkpoint inhibitors.
Review
Biochemistry & Molecular Biology
Kohei Matsuoka, Mizuki Yamada, Mitsuo Sato, Kazuhide Sato
Summary: The conventional treatment for thoracic tumors includes surgery, drugs, radiation, and immunotherapy. Recently, near-infrared photoimmunotherapy (NIR-PIT) has emerged as a promising therapeutic approach for thoracic tumors. By targeting different antigens, NIR-PIT can be applied to any desired target.
Article
Oncology
Hideyuki Furumoto, Ryuhei Okada, Takuya Kato, Hiroaki Wakiyama, Fuyuki Inagaki, Hiroshi Fukushima, Shuhei Okuyama, Aki Furusawa, Peter L. Choyke, Hisataka Kobayashi
Summary: Near-infrared photoimmunotherapy (NIR-PIT) is a cancer therapy that selectively destroys target cells by injecting monoclonal antibodies conjugated with a photon absorber and activating it with nonthermal doses of NIR light. Higher light doses can enhance the therapeutic effect but may cause local side effects, while lower doses can be effective and avoid side effects. This study determined the optimal light dose for NIR-PIT in an immunocompetent mouse model. It was found that a relatively low light dose is sufficient to achieve the maximum therapeutic effect without causing side effects.
Review
Nanoscience & Nanotechnology
Hiroaki Wakiyama, Takuya Kato, Aki Furusawa, Peter L. Choyke, Hisataka Kobayashi
Summary: Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer treatment that selectively kills cancer cells using targeting monoclonal antibodies and photoactivatable phthalocyanine-derivative dyes, leading to minimal damage to patients and rapid recovery. Additionally, it activates host antitumor immunity and enhances nanodrug delivery to tumor beds.
Article
Medicine, General & Internal
Kohei Matsuoka, Mizuki Yamada, Noriaki Fukatsu, Kyoichi Goto, Misae Shimizu, Ayako Kato, Yoshimi Kato, Hiroshi Yukawa, Yoshinobu Baba, Mitsuo Sato, Kazuhide Sato
Summary: Monitoring the effectiveness of NIR-PIT can be done by measuring SUPR. In this study, fluorescent signals and ultrasound imaging were used to evaluate SUPR, and indicators related to therapeutic effect were discovered.
Review
Medicine, Research & Experimental
Danfeng Wei, Jinxin Qi, Michael R. Hamblin, Xiang Wen, Xian Jiang, Hao Yang
Summary: NIR-PIT is a newly developed cancer treatment modality that targets tumors using a specific photosensitizer conjugate activated by NIR light. This treatment can induce immunogenic cell death and activate the adaptive immune response, as well as enhance drug delivery into tumors.
Review
Oncology
Takuya Kato, Hiroaki Wakiyama, Aki Furusawa, Peter L. Choyke, Hisataka Kobayashi
Summary: NIR-PIT utilizes an antibody-photoabsorber conjugate activated by NIR light to selectively kill cancer cells with minimal damage to normal cells, while also inducing a therapeutic host immune response. This approach has great potential in treating a variety of cancers and can be used in combination with other immunotherapies for enhanced effect.
Article
Oncology
Susumu Yamashita, Miho Kojima, Nobuhiko Onda, Makoto Shibutani
Summary: This study compared the properties and differences of near-infrared photoimmunotherapy (NIR-PIT) and photodynamic therapy (PDT) in terms of cellular binding/uptake specificity and cytotoxicity. NIR-PIT showed molecule-selective responses and cytotoxicity, while PDT showed non-selective cell type responses. Both NIR-PIT and PDT induced damage-associated molecular patterns (DAMPs), although PDT had different sensitivity between cell lines. Therefore, molecule-specific NIR-PIT may have advantages compared with PDT in terms of tumor visualization efficiency and induction of DAMPs.
Article
Oncology
Susumu Yamashita, Miho Kojima, Nobuhiko Onda, Toshinori Yoshida, Makoto Shibutani
Summary: Near-infrared photoimmunotherapy (NIR-PIT) is a novel treatment for HER2-positive cancers, including breast cancer, using conjugates of antibody against overexpressed antigens and photoabsorber IRDye700DX. This study investigated the efficacy of HER2-targeted NIR-PIT using trastuzumab-IRDye700DX conjugate (Tra-IR700) in HER2-positive breast cancer. The results showed that NIR-PIT with Tra-IR700 induced a highly selective therapeutic effect in a HER2-positive breast cancer model.
Article
Pharmacology & Pharmacy
Fang Li, Chengqiong Mao, Stacy Yeh, Yao Sun, Junbo Xin, Qin Shi, Xin Ming
Summary: This study demonstrates that the anti-MRP1 antibody (Mab)-IR700 conjugate shows higher cellular delivery in multidrug resistant SCLC cells, leading to a stronger photokilling effect and tumor suppression.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2021)
Article
Oncology
Taiki Moriya, Mayuko Hashimoto, Hina Matsushita, Shion Masuyama, Rina Yoshida, Ryuhei Okada, Aki Furusawa, Daiki Fujimura, Hiroaki Wakiyama, Takuya Kato, Peter L. Choyke, Yutaka Kusumoto, Tatyana Chtanova, Hisataka Kobayashi, Michio Tomura
Summary: Near-infrared photoimmunotherapy (NIR-PIT) selectively kills tumor cells and induces a systemic anti-tumor immune response. This study shows that NIR-PIT enhances migration of tumor-infiltrating dendritic cells (Ti-DCs) to draining lymph nodes (dLNs) via ATP-P2X7 receptor and G alpha i protein-coupled receptor signaling pathways, promoting tumor antigen presentation and the induction of anti-tumor T cells in dLNs.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Materials Science, Biomaterials
Yadan Zheng, Zhanzhan Zhang, Qi Liu, Ying Wang, Jialei Hao, Ziyao Kang, Chun Wang, Xinzhi Zhao, Yang Liu, Linqi Shi
Summary: An immunomodulating nano-photosensitizer was developed to enhance reactive oxygen species production and regulate the immunosuppressive tumor microenvironment for improved photoimmunotherapy. Through co-delivery of immunomodulators, this platform showed potential for efficient and precise treatment of tumors.
BIOMATERIALS SCIENCE
(2021)
Review
Biochemistry & Molecular Biology
Hideyuki Furumoto, Takuya Kato, Hiroaki Wakiyama, Aki Furusawa, Peter L. Choyke, Hisataka Kobayashi
Summary: Near-infrared photoimmunotherapy (NIR-PIT) is a promising therapy that uses antibody-photo-absorber conjugates (APCs) and NIR light to destroy target cells. It activates host antitumor immunity and can also produce responses in untreated lesions. The application of NIR-PIT with endoscopy has shown potential in the treatment of thoracic and gastrointestinal cancers.